Home - Nexcella, Inc

Our mission

is to improve patient outcomes in

AL Amyloidosis and select immune-mediated diseases

NEXICART-2 CLINICAL TRIAL

The NEXICART-2 clinical trial is dedicated to evaluating the safety and efficacy of our investigational CAR-T cell therapy (NXC-201) for patients with relapsed and refractory AL Amyloidosis.

Have you or a loved one undergone treatment for AL Amyloidosis without success?

Be part of a groundbreaking clinical trial exploring the potential of NXC-201, a cutting-edge CAR-T therapy designed for relapsed and refractory AL Amyloidosis.

Join the Future of AL Amyloidosis Treatment

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

$8 million grant funds development of NXC-201 in relapsed/refractory AL...

NexcellaJuly 26, 2024

Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States

Scheduling U.S. site initiation visits April and May 2024 On...

NexcellaApril 18, 2024

Nexcella Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board

Dr. Sanchorawala co-authored landmark study of daratumumab (DARZALEX®) in AL...

NexcellaJanuary 4, 2024

Nexcella Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board

Dr. Radic led and authored landmark study demonstrating applicability of...

NexcellaDecember 18, 2023

ABOUT NEXCELLA

Nexcella Inc., is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases.

Immix Biopharma (Nasdaq: IMMX) is the parent company of Nexcella Inc.

Transformative, one-time treatments with broader accessibility

Imagine a world where patients with AL amyloidosis and select immune-mediated diseases can receive transformative, one-time treatments with broader accessibility. At ImmixBio, we're pioneering CAR-T therapy by addressing the challenge of neurotoxicity, aiming to make these treatments available to more patients and medical centers across the U.S., starting with AL Amyloidosis. Read more about our groundbreaking technology and vision by visiting the Immix Biopharma website